New drug combo aims to shrink rectal tumors without radiation
NCT ID NCT07127497
Summary
This study is testing whether combining the immunotherapy drug sintilimab with standard chemotherapy (XELOX) before surgery can effectively shrink tumors in people with locally advanced rectal cancer. The approach specifically aims to avoid radiation therapy, which can have significant side effects. Researchers will measure how well the tumors respond and monitor safety in 50 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022, China
Conditions
Explore the condition pages connected to this study.